NCT00585585

Pilot Study of Betahistine Dihydrochloride in the Treatment of Major Depression With Atypical Features

A Pilot Study of Betahistine Dihydrochloride in the Treatment of Major Depression With Atypical Features

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: University of Cincinnati · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine a dose of the investigational drug betahistine dihydrochloride that is both well tolerated and potentially effective in treating the symptoms of atypical depression. Atypical depression is characterized by the ability of the person's mood to improve temporarily in response to positive events, as well as features such as increased appetite, increased sleep and severe fatigue.

Detailed description

All patients will start taking 50 mg of betahistine dihydrochloride on treatment day 1 (after baseline visit). Starting on day 4, the daily dose will be increased by adding a 50 mg dose. If tolerated, the daily dose will be titrated to 200 mg. At the end of week 3, the dose will be titrated to 300 mg.

Conditions

• Recurrent Major Depressive Disorder With Atypical Features

Interventions

Type	Name	Description
DRUG	betahistine dihydrochloride	oral, 50-300 mg, daily

Timeline

• Start date: 2007-07-01
• Primary completion: 2011-01-01
• Completion: 2011-01-01
• First posted: 2008-01-03
• Last updated: 2017-07-25
• Results posted: 2017-07-25

Locations

1 site across 1 country: United States